Physician profile
Laura Musser
NPI 1801878715
$1,583.75
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $223 · 2021: $519 · 2022: $435 · 2023: $41.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $41.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $41.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $182.33 | 2021-2022 | |
| Abbvie INC. | $139.81 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $134.29 | 2021-2022 | |
| Ethicon US, LLC | $126.54 | 2019-2020 | |
| Myovant Sciences INC. | $122.74 | 2021-2022 | |
| Agile Therapeutics, INC. | $119.55 | 2021-2022 | |
| Exeltis, USA INC. | $118.67 | 2019-2022 | |
| Pfizer INC. | $108.64 | 2019-2022 | |
| Coopersurgical, INC. | $91.23 | 2020-2022 | |
| Therapeuticsmd, INC. | $85.94 | 2019-2022 | |
| Hologic Sales and Service, LLC | $80.13 | 2019-2023 | Thinprep 2000 Processor |
| Avion Pharmaceuticals | $61.50 | 2019-2022 | |
| Lupin INC. | $58.84 | 2019-2020 | |
| Roche Diagnostics Corporation | $44.59 | 2019 | |
| Amgen INC. | $30.19 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $23.29 | 2021 | |
| Mylan Pharmaceuticals INC. | $19.69 | 2022 | |
| Allergan, INC. | $18.05 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.16 | 2019 | |
| Organon LLC | $2.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Musser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.